Inovimbisa Mhedzisiro muNew Pancreatic Cancer Study

SIWA Therapeutics, Inc., kambani yeChicago-based biopharmaceutical yakazivisa nhasi kuti SIWA's proprietary humanized monoclonal antibody, SIWA318H, inoshanda mune inodzivirira immune inokwanisa humanized mbeva xenograft modhi yepancreatic cancer. Chidzidzo ichi chakaitwa neTranslational Genomics research Institute ("TGEN"), zvichienderana nechibvumirano chetsvakiridzo chinotsigirwa neSIWA.

Mhedzisiro yekudzidza kwegomarara repancreatic mumakonzo akabatwa neSIWA318H aisanganisira:

• Zvose zviri zviviri SIWA318H dhigirii yepamusoro uye mapoka ekurapa mashoma anoratidza basa rakakosha rekurwisa bundu muPSN1 yevanhu pancreatic cancer mouse xenograft tumor model nekuderedza zvakanyanya kukura kwebundu (P-Value <0.0001);

• Paiva nenhamba yepamusoro yepamusoro yezviitiko zvekuregererwa zvakakwana mumapoka akabatwa achienzaniswa neboka rekutonga re-isotype.

o 37.5% (6 kunze kwe16 mbeva) yakabatwa neSIWA318H yepamusoro yepamusoro yakanga ine mhinduro yakakwana yekuregererwa; (P-kukosha = 0.0325)

o 43.8% (7 kunze kwe16 mbeva) yakabatwa neSIWA318H yakaderera dose yakanga ine mhinduro yakakwana yekuregererwa; (P-kukosha = 0.0143)

• SIWA318H yakarapa mbeva yakave nehupenyu hwakanaka hwemazuva anopfuura 45 zvichienzaniswa nemazuva 26 chete ehupenyu hwepakati pehupamhi hwehutongi hwemhuka, zvichiratidza zvakasimba zvingangobatsira kliniki yekurapa kenza yepancreatic muvanhu.

• Pakanga pasina misiyano yakakura mukushanduka kwehuremu hwemuviri pakati pekutonga uye mapoka ekurapa, zvichiratidza SIWA318H pamadhesi akashandiswa akaremerwa zvakanaka.

"Tinofara zvikuru nezvakawanikwa neSIWA318H muchidzidzo ichi uye zvinorevei mukurwisa gomarara," akadaro Lewis Gruber, CEO uye Chief Scientific Officer weSIWA. "SIWA yakagadzira kurwisa kwegomarara kwemativi maviri nekushandisa SIWA318H kubvisa maseru egomarara pamwe nemaseru emasero ari mubundu diki-nzvimbo inovatsigira. Isu tinotenda kugona uku kunanga ese ese maseru egomarara uye maseru anoita kuti SIWA318H ive yakazara immunotherapy kune angangoita ese magomarara pamwe nekumisa kukura kwegomarara, metastasis, uye kudzokazve. "

SIWA yakaratidza kuti zvichibva pamhedzisiro yayo nekenza yepancreatic uye metastasis, uye zvichibva pamhedzisiro inoratidza kudzikiswa kwakakosha kwemapapu metastases mune 4T1 mbeva modhi yekenza yemazamu katatu ichishandisa homolog yemuromo yeSIWA318H (P-value ≤ 0.001), inotarisira kuisa IND yayo yekutanga neFDA muna 2023 yegomarara repancreatic. Inotarisirawo kukumbira kuti FDA ipe FastTrack zita.